

DATE:	6 February 2023
TO:	All Pathologists and Hematologists/Oncologists in Alberta
FROM:	Molecular Pathology Program, Alberta Precision Laboratories
RE:	Sendout Testing for Fusions in Solid Tumors

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- The molecular pathology lab reagent shortage issue has been resolved, which affected in-house fusion panel RNA next generation sequencing (NGS) requests on solid tumors on the Pan-Solid Tumor Fusion Panel and Lung Fusion Panel (Kinase Fusion Panel). In-house testing is resumed.

Background

- As per the laboratory bulletin distributed on December 1, 2022, all fusion panel RNA next generation sequencing (NGS) requests on solid tumors received on or after November 29 2022 that would normally have been tested in Calgary, were sent out for external testing until further notice. This included all indications for Pan-Solid Tumor Fusion Panel and Lung Fusion Panel (Kinase Fusion Panel).
- There was a critical shortage of reagents needed to perform Archer FusionPlex RNA NGS testing, which impacted the Pan-Solid Tumor Fusion Panel and Lung Fusion Panel (Kinase Fusion Panel) that are performed in Calgary for provincial testing. Multiple different sendout assays were utilized on a case-by-case basis depending on the clinicopathologic context, including Mayo Clinic Laboratories and University of Washington assays.
- Reagents are now fully stocked in the Molecular Pathology laboratory.

How this will impact you

- In-house testing is now resumed for fusion panel RNA NGS on solid tumors.

Action Required

- **Pathologists and Oncologists:** Please continue to submit fusion panel requests in the same way.

Effective January 20, 2023

Questions/Concerns

- Erik Nohr, Scientific Lead, Molecular Pathology South erik.nohr@albertaprecisionlabs.ca
- Adrian Box, Medical/Scientific Director, Molecular Pathology Program Adrian.box@albertaprecisionlabs.ca
- Cheryl Mather, Medical Lead, Molecular Pathology North cheryl.mather@albertaprecisionlabs.ca

Approved by

- Adrian Box, Medical/Scientific Director, Molecular Pathology Program
- Mark Douesnard, Operations Director, Molecular Pathology Program